Recombinant Human GRO-α/CXCL1 #abs01103

abs01103-5ug

1-2 Weeks

138

abs01103-25ug

1-2 Weeks

344

abs01103-1mg

1-2 Weeks

3891

Species

Human

Source

Escherichia coli.

Format

In 20 mM PB, pH 7.4, 150 mM NaCl, the concentrated solution was filtered through a 0.2 μm filter and then lyophilized.

Properties

aa_sequence

SNDKMLKEII KVIPSPANLC AKRGNLKTIA VETQACPHPG SKVNVSQINK PHIGQTLQCL CRLEVTAHSA QCQITLAVSE.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The level of Recombinant HumanGRO-α/CXCL1 was determined to be below 1 EU/μg using the LAL method. Let me generate an alternative content that conveys the same information in a different way:
The LAL method was employed to assess the presence of Endotoxin Units (EU) per microgram (μg) of Recombinant HumanGRO-α/CXCL1. The results indicate that the measured amount is less than 1 EU/μg.

Activity

The standard and the fully biologically active compound exhibit comparable activity levels. This activity was assessed using a chemotaxis bioassay with human peripheral blood neutrophils. The effective concentration range for this bioactivity was found to be 10-50 ng/ml.

Reconstitution

To ensure proper mixing, it is advised to briefly centrifuge the vial prior to opening. Reconstitute the contents in sterile distilled water or an aqueous buffer containing 0.1% BSA, aiming for a concentration of 0.1-1.0 mg/ml. Remember to divide the stock solution into smaller working aliquots and store them at -20 °C or below. For further dilutions, use suitable buffered solutions.

Stability & Storage

This lyophilized preparation can be stored at 2-8 °C, but for long-term storage, it is advisable to keep it at -20 °C, preferably in a desiccated state. Once reconstituted, the preparation can remain stable for up to one week at 2-8 °C. For optimal stability, it is recommended to divide the reconstituted preparation into working aliquots and store them at -20 °C to -70 °C. It is important to avoid any freeze/thaw cycles as they can impact the stability of the preparation.

Target

Accession

P09341

Gene IDs

2919

References

References

1. Haskill S, Peace A, Morris J, et al. 1990. Proc Natl Acad Sci U S A. 87:7732-6.

2. Anisowicz A, Bardwell L, Sager R. 1987. Proc Natl Acad Sci U S A. 84:7188-92.

3. Richmond A, Thomas HG. 1988. J Cell Biochem. 36:185-98.

4. Iida N, Grotendorst GR. 1990. Mol Cell Biol. 10:5596-9.

5. Tsai HH, Frost E, To V, et al. 2002. Cell. 110:373-83.

6. Moser B, Clark-Lewis I, Zwahlen R, et al. 1990. J Exp Med. 171:1797-802.

7. Devalaraja RM, Nanney LB, Du J, et al. 2000. J Invest Dermatol. 115:234-44.